Johnna Perdrizet

Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States

Liping Huang, Matt Wasserman, Lindsay R. Grant et al. · Vaccine · 2022 · 44 citations · Full text

Vaccination, Vaccine Safety, Pediatric Epidemiology +13

Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age

Matt Wasserman, Johnna Perdrizet, Lindsay R. Grant et al. · Infectious Diseases and Therapy · 2021 · 40 citations · Full text

Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population

Derek Lytle, Ana Gabriela Grajales Beltrán, Johnna Perdrizet et al. · Human Vaccines & Immunotherapeutics · 2023 · 33 citations · Full text

Cost-effectiveness Analysis, Dominant Strategy, Canadian Infants +20

Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis

An Ta, Felicitas Kühne, Maren Laurenz et al. · Infectious Diseases and Therapy · 2024 · 33 citations · Full text

Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States

Johnna Perdrizet, Emily K. Horn, Kyla Hayford et al. · Infectious Diseases and Therapy · 2023 · 31 citations · Full text